93 results on '"*METASTATIC breast cancer"'
Search Results
2. Approaches for Enhanced Extrapolation of Long-Term Survival Outcomes Using Electronic Health Records of Patients With Cancer.
3. SA21 Feasibility Assessment of an Indirect Treatment Comparison (ITC) of Sacituzumab Govitecan (SG) Vs Trastuzumab Deruxtecan (T-DxD) in HR+/HER2– Metastatic Breast Cancer (mBC).
4. RWD50 Evaluation and Improvement of a NHDS Algorithm to Detect Patients With Metastatic Breast Cancer and HER2+ Status Using a RWE NLP-Powered Solution.
5. PCR75 Real-World Evidence of Outcomes of Fulvestrant Monotherapy After Progression on CDK4/6 Inhibitor + Aromatase Inhibitor in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer.
6. MT37 Clinical Utility of Circulating Tumor Cell (CTC) Enumeration-Based Liquid Biopsy and HER2 CTC Assessment in Patients with Metastatic Breast Cancer: Overview of Current Available Data and Interventional Trials.
7. HPR184 Social Determinants of Health (SDoH) and Other Predictors in Treatment Initiation with CDK4/6 Inhibitors in Medicare Patients with HR+/HER2– Metastatic Breast Cancer (MBC).
8. EE166 Cost-Effectiveness of Alpelisib Plus Fulvestrant in Postmenopausal Women with Hr+/HER2- Advanced Breast Cancer (ABC) in Qatar.
9. Response Shift-Adjusted Treatment Effect on Health-Related Quality of Life in a Randomized Controlled Trial of Taxane Versus S-1 for Metastatic Breast Cancer: Structural Equation Modeling.
10. HSD107 Recommendations for the Design and Implementation of a Multidisciplinary Consensus Guidance for Clinical Practice on Advanced Breast Cancer in Portugal.
11. EE391 A Systematic Literature Review (SLR) of Economic Burden of Patients with Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2–) Metastatic Breast Cancer (MBC) with at Least One Prior Therapy.
12. EE280 Real-World Healthcare Resource Utilization of Patients with Metastatic Breast Cancer: A Retrospective Cohort Analysis.
13. EE46 Cost-Effectiveness of Alpelisib Plus Fulvestrant in Postmenopausal Women with Hr+/HER2- Advanced Breast Cancer (ABC) in Oman.
14. CO119 Clinical Utility of Circulating Tumor Cell Enumeration-Based Liquid Biopsy in Patients with Metastatic Breast Cancer: A Review of the Peer-Reviewed Clinical Literature.
15. P43 Critical Appraisal of Drug Pricing for Advanced Breast Cancer Medications Approvals in Brazil (2007 - 2022) and Comparison with Major National Economic Indicators.
16. P5 Measures of Neighborhood Structural Racism and Overall Survival Among Patients with Metastatic Breast Cancer.
17. CO121 The Impact of Clinical Trial Participation on Patients with Metastatic Breast Cancer.
18. SA27 Comparison of Comorbidity Indices Between Electronic Health Records (EHR) Derived Database and Claims Data Among Patients With Metastatic Breast Cancer.
19. RWD74 Real-World Effectiveness of CDK 4/6 Inhibitor as First-Line Treatment in Patients With HR+, HER2- Advanced Breast Cancer in South Korea - Focused on Underrepresented Younger and Older Age.
20. MSR128 Swedish Nationwide Register Data as a Low-Cost Resource to Detect Drug-Repurposing Signals: A Study on De Novo Metastatic Breast Cancer Patients.
21. HSD21 Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced/Metastatic Breast Cancer (ABC): Testing Patterns, Prescribing Behavior, and Treatment Option Perceptions Among U.S. Oncologists.
22. EE361 Cost-Effectiveness Analysis of Ribociclib Versus Abemaciclib in the First-Line (1L) Treatment of Postmenopausal Women With HR+/HER2- Advanced Breast Cancer (ABC).
23. EE291 Economic Evaluation of Metastatic Breast Cancer Following Trastuzumab-Based Treatment of HER2+ Early Breast Cancer in Hong Kong.
24. EE213 Cost-Effectiveness Analysis of Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer.
25. POSC256 Application of Progression-Free Survival As Surrogate Endpoint for Overall Survival in Nice Reviews of Advanced Breast Cancer Drugs.
26. EE459 Is Adding Ribociclib to Fulvestrant Cost-Effective in Treating Post-Menopausal Women with HR+/ HER2- Advanced Breast Cancer - a US Payer Perspective Cost-Utility Analysis.
27. EE372 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative Advanced/Metastatic Breast Cancer in Colombia.
28. PCN312 In Advanced/Metastatic Breast Cancer, Is Progression-Free Survival a Surrogate Outcome?
29. PCN79 IMPACT of Adjuvant Trastuzumab Emtansine (T-DM1) on the Incidence of HER2-Positive Metastatic Breast Cancer and Its Associated Savings for the Spanish National Healthcare System.
30. PCN69 Cost-Effectiveness Analysis of NOVEL Therapies for HER2+ Metastatic Breast Cancer: [FAM-] Trastuzumab Deruxtecan Versus Tucatinib Trastuzumab and Capecitabine Combination.
31. POSB384 A Systematic Literature Review of Economic Evidence in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Positive Advanced or Metastatic Breast Cancer.
32. POSA410 Cancer Subtypes and Systemic Antineoplastic Treatment Utilization Among Patients with Advanced Breast Cancer Across Large Community Health Systems in the US.
33. POSA396 Work Productivity in Patients with Metastatic Breast Cancer: A Retrospective Analysis of Claims Data in the U.S.
34. POSC151 Cost-Effectiveness Analysis of Ribociclib in Ecuadorian Women with Advanced Breast Cancer.
35. POSC129 Economic Burden of Metastatic Breast Cancer in Greece.
36. POSB120 Economic Assessment of Ribociclib for the Treatment of Postmenopausal Patients with Advanced Breast Cancer HR-Positive, HER2-Negative.
37. POSB93 Conversion from Subcutaneous Trastuzumab to Trastuzumab-Dkst in Metastatic Breast Cancer: Comparative Cost-Efficiency Modelling between US and France.
38. POSA116 Cost-Utility of Ribociclib As the First-Line Treatment in Postmenopausal Women with Advanced/Metastatic Breast Cancer, Hormone Receptor Positive and Human Epidermal Growth Factor Receptor-2 Negative in Colombia.
39. POSB19 Matching-Adjusted Indirect Comparison of Trastuzumab Deruxtecan vs. Eribulin, Capecitabine, and Vinorelbine for Treating Human Epidermal Growth Factor Receptor 2-Positive Unresectable or Metastatic Breast Cancer after Two or More Anti-Human Epidermal Growth Factor Receptor 2-Positive Therapies
40. POSB5 Real-World Patterns of Treatment and Dose Modification with CDKI 4/6 for Advanced Breast Cancer in Portugal.
41. Progression-Free Survival with Fulvestrant 500 mg and Alternative Endocrine Therapies as Second-Line Treatment for Advanced Breast Cancer: A Network Meta-Analysis with Parametric Survival Models
42. PCN275 BENEFITS AND CHALLENGES OF MOBILE HEALTH APPLICATIONS IN PROSPECTIVE STUDIES: LEARNINGS FROM THE MADELINE STUDY AND LITERATURE.
43. PCN228 TREATMENT PATTERNS AND PROGNOSTIC FACTORS OF LOCALLY ADVANCED OR METASTATIC HR+ / HER2- BREAST CANCER IN ARGENTINA.
44. PCN65 THE CHALLENGE OF VALUE-BASED PRICING IN COMBINATION THERAPY:THE CASE OF TRASTUZUMAB AND PERTUZUMAB IN HER2+ METASTATIC BREAST CANCER.
45. TP1 GUIDELINE-CONCORDANT TREATMENT AND ITS IMPACT ON SURVIVAL AND COSTS AMONG ELDERLY WOMEN WITH HER2-NEGATIVE METASTATIC BREAST CANCER.
46. PDG11 COST MINIMIZATION ANALYSIS OF TRASTUZUMAB SUBCUTANEOUS VERSUS INTRAVENOUS IN TREATMENT OF HER2-POSITIVE EARLY OR METASTATIC BREAST CANCER IN VIETNAM.
47. MS3 PREDICTING OPTIMAL TREATMENT REGIMENS FOR HR+/HER2- BREAST CANCER BASED ON ELECTRONIC HEALTH RECORDS USING RANDOM FOREST.
48. PCN160 COST-EFFECTIVENESS OF RIBOCICLIB PLUS LETROZOLE COMPARED TO PALBOCICLIB PLUS LETROZOLE IN THE FIRST-LINE TREATMENT OF POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR-POSITIVE/HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HR+/HER2-) ADVANCED OR METASTATIC BREAST CANCER (ABC): A BRAZILIAN PRIVATE PAYER PERSPECTIVE
49. PCN103 Cost-Effectiveness of Palbociclib in Combination with Letrozole Versus Letrozole ALONE for Patients with Advanced or Metastatic Breast Cancer HR+ / HER2- in the Brazilian Public Healthcare System.
50. PCN49 Biosimilar Trastuzumab Mono- and Pertuzumab Combination Therapy in Metastatic Breast Cancer: Cost Efficiency and Expanded Access Modeling.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.